Published by the IC
nternational M I
yeloma FT
oundation
IN
Special Edition: G
ASCO 2010
SQ2/2010
American Society of Clinical Oncology (ASCO)
2010 Presentations Issue
Welcome to the International Myeloma Foundation's (IMF) special edition of CITINGS, our premiere publication featuring
the most up-to-date information on myeloma treatment and diagnostics.
This issue focuses on presentations at the 2010 Annual American Society of Clinical Oncology Meeting on June 4-8, 2010
in Chicago, Illinois. For your convenience, and to help you better navigate the conference, we have listed below the oral,
poster, and publication-only presentations relevant to multiple myeloma.
As always, please feel free to contact the IMF at (800) 452-2873 (CURE) or at www.myeloma.org.
­ Susie Novis, President, IMF
Friday, June 4, 2010
Afternoon Poster Session /Posters with Discussion Session
Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex)
(CRd) in relapsed/refractory multiple myeloma (R/R MM).
W. Bensinger, M. Wang, R. Z. Orlowski, M. Alsina, T. Martin, S. Singhal, N. Y. Gabrail, M. Vallone, M. Kauffman,
R. Niesvizky.
General Poster Session: Lymphoma and Plasma Cell Disorders Abstract 8029
Time: 2:00 PM to 6:00 PM
Location: E450a
Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment
of AL amyloidosis (AL) and/or high-risk myeloma (hM): Analysis of a Southwest Oncolog y Group trial.
V. Sanchorawala, V. Bolejack, J. Crowley, A. Hoering, K. T. Finn, S. Fennessey, D. C. Seldin, B. Barlogie.
Poster: 2:00 PM to 6:00 PM Abstract 8022
Location: E450a
Discussion: 5:00 PM to 6:00 PM
Location: E354b
Outcome with total therapy 3 (TT3) compared to total therapy 2 (TT2): Role of GEP70-defined high-risk
disease with trisomy of 1q21 and activation of the proteasome gene PSMD4.
J. D. Shaughnessy, P. Qu, E. Tian, R. Edmondson, B. P. Nair, S. Waheed, Y. Alsayed, F. Van Rhee, J. Haessler, J. Crowley,
B. Barlogie.
General Poster Session: Lymphoma and Plasma Cell Disorders Abstract 8027
Time: 2:00 PM to 6:00 PM
Location: E450a
Phase I study of combined vorinostat ( V), lenalidomide (L), and dexamethasone (D) in patients (pts)
with relapsed or refractory multiple myeloma (MM).
P. G. Richardson, D. M. Weber, C. S. Mitsiades, M. A. Dimopoulos, J. Harousseau, J. Howe, T. Graef, C. Byrne,
K. C. Anderson, D. S. Siegel.
General Poster Session: Lymphoma and Plasma Cell Disorders Abstract 8031
Time: 2:00 PM to 6:00 PM
Location: E450a
www.myeloma.org
(800) 452 - CURE (2873)
Funded by unrestricted educational grants from Celgene Corporation and Millennium: The Takeda Oncology Company.
Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients
(Pts) with relapsed (Rel) or Rel and refractory (Ref ) multiple myeloma (MM).
M. Mateos, A. Spencer, K. Taylor, S. Lonial, J. De La Rubia, T. Facon, B. Bengoudifa, K. Hazell, P. M. Bourquelot,
J. F. San-Miguel.
Poster: 2:00 PM to 6:00 PM Abstract 8030
Location: E450a
Discussion: 5:00 PM to 6:00 PM
Location: E354b
Response of newly diagnosed myeloma with 1q21 amplification to bortezomib-based PAD induction therapy.
D. E. Joshua, J. Bashford, J. Szer, N. Horvath, A. Spencer, M. S. Hertzberg, E. Ashurst, J. Wade, M. C. Copeman,
H. M. Prince.
Poster: 2:00 PM to 6:00 PM Abstract 8028
Location: E450a
Discussion: 5:00 PM to 6:00 PM
Location: E354b
Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory
multiple myeloma.
A. K. Mahindra, P. G. Richardson, P. Hari, J. Laubach, I. M. Ghobrial, R. L. Schlossman, E. Weller, N. C. Munshi,
K. C. Anderson, N. S. Raje.
Poster: 2:00 PM to 6:00 PM Abstract 8032
Location: E450a
Discussion: 5:00 PM to 6:00 PM
Location: E354b
Saturday, June 5, 2010
Morning Poster Session
A comparison of lenalidomide/dexamethasone (RD) versus cyclophosphamide/ lenalidomide/ dexamethasone
(CRD) versus cyclophosphamide/bortezomib/dexamethasone (CyborD) in newly diagnosed multiple myeloma
(MM).
M. L. Khan, C. B. Reeder, S. Kumar, M. Lacy, D. E. Reece, K. M. Laumann, J. Mikhael, R. Fonseca, V. Rajkumar,
A. K. Stewart.
General Poster Session: Lymphoma and Plasma Cell Disorders Abstract 8131
Time: 8:00 AM to 12:00 PM
Location: S Hall A2
Activity of the NEDD8-specific inhibitor MLN 4924 in multiple myeloma and Waldenström's
macroglobulinemia, and effect on miRNA expression.
D. W. McMillin, Z. R. Hunter, J. Delmore, P. Smith, A. Birner, P. G. Richardson, K. C. Anderson, S. P. Treon,
C. S. Mitsiades.
General Poster Session: Lymphoma and Plasma Cell Disorders Abstract 8110
Time: 8:00 AM to 12:00 PM
Location: S Hall A2
An evaluation of the role of bone marrow biopsy in patients with multiple myeloma who achieve
an unconfirmed stringent complete remission.
T. M. Mark, A. Koirala, R. N. Pearse, F. Zafar, D. Jayabalan, J. P. Leonard, M. Coleman, R. Niesvizky.
General Poster Session: Lymphoma and Plasma Cell Disorders Abstract 8144
Time: 8:00 AM to 12:00 PM
Location: S Hall A2
www.myeloma.org
(800) 452 - CURE (2873)
A phase I study of IPH2101, a novel anti-inhibitory KIR monoclonal antibody, in patients
with multiple myeloma.
D. M. Benson, S. Padmanabhan, C. C. Hofmeister, C. E. Bakan, R. Abonour, A. Suvannasankha, Y. A. Efebera,
P. J. Squiban, M. A. Caligiuri, S. Farag.
General Poster Session Lymphoma and Plasma Cell Disorders, Abstract 8139
Time: 8:00 AM to 12:00 PM
Location: S Hall A2
A phase I study of the anti-kappa monoclonal antibody, MDX-1097, in previously treated multiple myeloma
patients.
A. Spencer, P. Walker, P. Asvadi, M. Wong, D. Campbell, K. Reed, M. C. Copeman, G. Nichol, L. J. Cohen, R. Dunn.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8143
Time: 8:00 AM to 12:00 PM
Location: S Hall A2
A phase II study of a modified peg ylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone
regimen for patients with previously untreated multiple myeloma (MM).
J. R. Berenson, O. Yellin, C. Chen, R. Patel, A. Bessudo, R. V. Boccia, H. Yang, V. Gupta, J. Hilger, R. A. Swift.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8134
Time: 8:00 AM to 12:00 PM
Location: S Hall A2
Association of hyperphosphorylated paratarg-7, the first autosomal-dominantly inherited risk factor
for hematological neoplasms, with MGUS and multiple myeloma in different ethnic groups.
S. Grass, S. Iida, A. Wikowicz, N. Fadle, A. Inagaki, K. Preuss, M. Ziepert, R. Ueda, M. Pfreundschuh.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8111
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
BIK (Bcl2-Interacting Killer) CpG methylation status as a potential predictive biomarker of relapsed/refractory
multiple myeloma disease.
E. Hatzimichael, A. Dasoula, G. Dranitsaris, A. Vassou, A. Papoudou-Bai, J. Stebbing, K. Bourantas, T. Crook.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8118
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma.
N. S. Raje, N. C. Munshi, A. K. Mahindra, S. Pozzi, P. G. Richardson, J. Laubach, I. M. Ghobrial, R. L. Schlossman,
K. C. Anderson.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8140
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Bortezomib and high-dose melphalan as conditioning regimen before transplantation for de novo multiple
myeloma patients: Updated data of the IFM phase II study.
M. Roussel, P. Moreau, A. Huynh, J. Mary, D. Caillot, C. Hullin, C. Mathiot, H. Avet-Loiseau, J. Harousseau, M. Attal.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8129
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Bortezomib and dexamethasone from cycle 1 as treatment and maintenance for multiple myeloma relapse
(The BoMeR trial): Impact on response and time to progression.
S. J. Harrison, H. Quach, J. Dean, A. Milner, M. C. Copeman, H. M. Prince.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8151
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
www.myeloma.org
(800) 452 - CURE (2873)
Cure fractions (CF) modeled from event-free survival and complete response duration plots in total therapy
(TT) trials for newly diagnosed multiple myeloma (MM).
J. Crowley, J. D. Shaughnessy, V. Bolejack, E. J. Anaissie, F. Van Rhee, B. Barlogie.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8119
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Does the magnitude of response to initial induction therapy impact plans for immediate autologous
stem cell transplant (ASCT) consolidation in the transplant-eligible patient with a new diagnosis
of multiple myeloma (MM)?
J. Willey, K. E. Lemke, M. E. Williams, M. R. Green, S. Lonial.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8146
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Expression of erythropoietin receptors by plasma cells from patients with multiple myeloma:
Potential relevance to pharmacological use of erythropoietin.
P. S. Becker, C. P. Miller, B. L. Wood, S. Chien, W. Bensinger, F. Shahijanian, C. A. Blau.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8124
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Gene expression profiling (GEP) analysis of CD138-purified plasma cells (PC) obtained from MRI-defined
focal lesions (FL) under CT guidance: Applying the 70 gene risk model and comparison with data generated
on random samples (RS) from multiple myeloma (MM) treated with total therapy 2, 3, 4, and 5 (TT2, TT3,
TT4, and TT5).
Y. Qiang, R. van Hemert, T. Brown, J. D. Shaughnessy, F. Van Rhee, A. Hoering, B. Barlogie.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8126
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Genomic evolution in total therapy 2 (TT2) and total therapy 3 (TT3) for newly diagnosed multiple myeloma
(MM): Comparison of baseline (BL) and relapse (REL) gene expression profiling (GEP) signatures.
A. Hoering, J. D. Shaughnessy, J. Haessler, R. Sexton, F. Van Rhee, Y. Alsayed, S. Waheed, B. P. Nair, J. Crowley,
B. Barlogie.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8120
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor.
S. Z. Usmani, R. D. Bona, G. Chiosis, Z. Li.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8141
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Metaphase cytogenetic abnormalities (M-CA) in multiple myeloma (MM): Examining number of M-CA
for survival in total therapy protocols (TT1, TT2, TT3).
J. Haessler, B. P. Nair, J. Sawyer, A. Hoering, J. D. Shaughnessy, B. Barlogie.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8123
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
www.myeloma.org
(800) 452 - CURE (2873)
MP versus MPT for previously untreated elderly patients with multiple myeloma:
A meta-analysis of 1,682 individual patient data from six randomized clinical trials.
A. Waage, A. P. Palumbo, P. Fayers, M. Beksac, C. Hulin, J. Mary, S. Bringhen, P. Sonneveld, P. Wijermans, T. Facon.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8130
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Multiple myeloma is characterized by widespread epigenomic alterations with prognostic implications.
C. J. Heuck, J. Mehta, N. Pulliam, R. Meagher, L. Zhou, E. Vickrey, E. Voigt, J. Greally, A. Verma, S. Singhal.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8117
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging.
K. Belhadj, C. Lin, A. Luciani, T. EL Gnaoui, I. Gaillard, J. Dupuis, F. Kuhnowski, M. Bedoui, A. Rahmouni, C. Haioun.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8150
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Neurotoxic and peripheral neuropathic effects in preclinical and clinical studies of carfilzomib (CFZ),
a novel proteasome inhibitor (PI).
J. L. Wolf, R. Vij, S. Lonial, M. Wang, S. Jagannath, S. Singhal, M. H. Le, C. Kirk, S. Arastu-Kapur, D. S. Siegel.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8135
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Phase I trial of ARRY-520 in relapsed/refractory multiple myeloma (RR MM).
J. J. Shah, A. D. Cohen, J. A. Zonder, J. L. Kaufman, S. M. Burt, B. B. Freeman, S. Rush, A. M. Ptaszynski,
R. Z. Orlowski, S. Lonial.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8132
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency.
A. Z. Badros, R. Vij, T. Martin, J. A. Zonder, A. F. Wong, T. Woo, K. Boussina, Z. Wang, R. Niesvizky.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8128
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Predicting 10+ year survivors in total therapy 1 (TT1) for multiple myeloma (MM).
S. Waheed, Y. Alsayed, R. Sexton, A. Hoering, B. Barlogie.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8138
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Primary plasma cell leukemia (PCL): Clinical and laboratory presentation and clinical outcome with
total therapy (TT) protocols.
B. P. Nair, N. Petty, S. Waheed, A. Hoering, F. Van Rhee, E. J. Anaissie, R. Lorsbach, C. Bailey, B. Barlogie.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8116
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Racial disparities in incidence and survival among 37,977 blacks and whites with multiple myeloma.
A. J. Waxman, P. Mink, S. Devesa, W. F. Anderson, B. M. Weiss, S. Kristinsson, K. McGlynn, O. Landgren.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8115
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
www.myeloma.org
(800) 452 - CURE (2873)
Retrospective analysis of multiple myeloma survival outcomes in veterans:
Focus on racial differences, age, and novel therapies.
D. I. Da Graca, S. Yellapragada, Z. Yasin, C. E. Arce-Lara; Michael E. DeBakey.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8127
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Single-agent everolimus (RAD001) in patients with relapsed or refractory multiple myeloma:
Final results of a phase I study.
A. Guenther, P. Baumann, R. Burger, W. Klapper, R. Schmidmaier, M. Gramatzki.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8137
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Single/tandem autologous hematopoietic progenitor cell transplantation in high-risk de novo multiple
myeloma patients: A retrospective analysis.
M. V. Martino, R. Fedele, G. Console, G. Irrera, G. Messina, C. Stelitano, M. Brugiatelli, C. Musolino, S. Molica,
P. Iacopino.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8145
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Stromal elements and engraftment (ENG) in autologous hematopoietic progenitor cell transplant (autoHCT)
for myeloma.
M. Veeraputhiran, Z. Singh, B. Barlogie, M. Cottler-Fox.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8149
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
The Arkansas experience with autotransplantation (AT) for older patients (OP, age > 65) with multiple
myeloma (MM).
E. J. Anaissie, M. Grazziutti, J. Szymonifka, B. P. Nair, F. Van Rhee, Y. Alsayed, S. Waheed, A. Hoering, B. Barlogie.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8136
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing
of maintenance components dexamethasone (D), thalidomide (T) and bortezomib ( V).
F. Van Rhee, B. Barlogie, J. Szymonifka, E. J. Anaissie, B. P. Nair, S. Waheed, Y. Alsayed, N. Petty, J. D. Shaughnessy,
A. Hoering, J. Crowley.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8121
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to
bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study.
S. Kumar, J. Crowley, S. K. Klein, J. J. Lahuerta, J. Lee, P. Moreau, G. Morgan, P. G. Richardson, D. S. Siegel, B. G. Durie.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8125
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
www.myeloma.org
(800) 452 - CURE (2873)
Update on vantage program to assess combined vorinostat ( V) and bortezomib (B) in patients (pts)
with relapsed and/or refractory (RR) multiple myeloma (MM).
S. Jagannath, D. S. Siegel, R. Hajek, M. A. Dimopoulos, S. Yoon, S. Lonial, T. Graef, L. Lupinacci, D. Reiser,
K. C. Anderson.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8133
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Updated results of a phase Ib/II study of carfilzomib (CFZ) in patients (pts) with relapsed malignancies.
P. Lee, A. F. Wong, H. A. Burris III, K. Papadopoulos, E. A. Sausville, P. J. Rosen, D. S. Mendelson, J. R. Infante,
A. Patnaik, M. S. Gordon.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8147
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Use of bortezomib to overcome the poor prognosis of t(4;14), but not del(17p), in young patients
with newly diagnosed multiple myeloma.
H. Avet-Loiseau, P. Moreau, C. Mathiot, C. Charbonnel, T. Facon, M. Attal, C. Hulin, G. Marit, S. Minvielle,
J. Harousseau.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8113
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Use of combined FDG-PET and laboratory data for predicting relapse in multiple myeloma.
B. M. Elliott, S. Peti, D. Lee, K. Osman, L. M. Isola, E. Scigliano, L. Kostakoglu.
General Poster Session: Lymphoma and Plasma Cell Disorders, Abstract 8148
Time: 8:00 AM to 12:00 PM.
Location: S Hall A2
Saturday, June 5, 2010
Afternoon Clinical Science Symposium:
Novel Therapies for Myeloma
Activity of pomalidomide plus dexamethasone (Pom/dex) in dual lenalidomide/bortezomib refractory
multiple myeloma (MM).
M. Lacy, M. A. Gertz, S. R. Hayman, A. Dispenzieri, S. Kumar, J. Mikhael, A. K. Stewart, J. Allred, S. J. Mandrekar,
S. V. Rajkumar.
Clinical Science Symposium: Novel Therapies for Myeloma, Abstract 8002
Time: 4:30 PM to 6:00 PM
Location: E354a
Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma:
A phase I study.
A. J. Jakubowiak, D. M. Benson Jr., W. Bensinger, D. S. Siegel, T. M. Zimmerman, A. Mohrbacher, P. G. Richardson,
D. Afar, A. K. Singhal, K. C. Anderson.
Clinical Science Symposium: Novel Therapies for Myeloma, Abstract 8003
Time: 4:30 PM to 6:00 PM
Location: E354a
www.myeloma.org
(800) 452 - CURE (2873)
Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed
(Rel) or Rel and refractory (Ref ) multiple myeloma (MM).
J. F. San-Miguel, O. Sezer, D. S. Siegel, A. Guenther, J. Blade, I. W. Prosser, B. Bengoudifa, M. Klebsattel,
P. M. Bourquelot, K. C. Anderson.
Clinical Science Symposium: Novel Therapies for Myeloma, Abstract 8001
Time: 4:30 PM to 6:00 PM
Location: E354a
Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory
multiple myeloma (R/R MM).
R. Vij, D. S. Siegel, J. L. Kaufman, A. J. Jakubowiak, A. K. Stewart, S. Jagannath, V. Kukreti, M. H. Le, M. K. Bennett,
M. Wang.
Clinical Science Symposium: Novel Therapies for Myeloma, Abstract 8000
Time: 4:30 PM to 6:00 PM
Location: E354a
Sunday, June 6, 2010
Morning Oral Session
A phase III trial of melphalan/prednisone/lenalidomide (MPR) versus melphalan (200 mg/m2) and autologous
transplantation (MEL200) in newly diagnosed myeloma patients.
A. P. Palumbo, F. Cavallo, F. Di Raimondo, D. Ben Yehuda, P. Omedè, V. Montefusco, F. Rossini, I. Hardan, T. Caravita,
M. Boccadoro.
Oral Abstract Session: Myeloma, Abstract 8134
Time: 9:30 AM to 12:30 PM
Location: E354b
Bortezomib, melphalan, prednisone, and thalidomide ( VMPT) followed by maintenance with bortezomib and
thalidomide ( VT) for initial treatment of elderly multiple myeloma patients.
M. Boccadoro, S. Bringhen, G. Gaidano, R. Ria, M. Offidani, F. Patriarca, C. Nozzoli, P. Musto, M. Petrucci,
A. P. Palumbo.
Oral Abstract Session: Myeloma, Abstract 8013
Time: 9:30 AM to 12:30 PM
Location: E354b
Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib
plus dexamethasone ( VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM):
Results of IFM2007-02 study.
P. Moreau, T. Facon, M. Attal, C. Doyen, C. Hulin, G. Marit, L. Garderet, M. Tiab, H. Avet-Loiseau, J. Harousseau.
Oral Abstract Session: Myeloma, Abstract 8014
Time: 9:30 AM to 12:30 PM
Location: E354b
Defining the prognostic variables in gene expression profiling (GEP)-defined high-risk multiple myeloma
(MM): Distinguishing early failures (EF) from sustained control (SC).
B. Barlogie, J. D. Shaughnessy, J. Haessler, A. Hoering, F. Van Rhee, E. J. Anaissie, J. Crowley
Oral Abstract Session: Myeloma, Abstract 8019
Time: 9:30 AM to 12:30 PM
Location: E354b
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory
multiple myeloma: A phase I/II study.
S. Lonial, R. Vij, J. Harousseau, T. Facon, P. Moreau, X. Leleu, C. Westland, A. K. Singhal, S. Jagannath.
Oral Abstract Session: Myeloma, Abstract 8020
Time: 9:30 AM to 12:30 PM
Location: E354b
www.myeloma.org
(800) 452 - CURE (2873)
Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple
myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX study.
G. Morgan, F. Davies, W. Gregory, S. E. Bell, A. Szubert, N. Navarro Coy, M. Drayson, R. G. Owen, G. H. Jackson,
J. A. Child.
Oral Abstract Session: Myeloma, Abstract 8021
Time: 9:30 AM to 12:30 PM
Location: E354b
Lenalidomide maintenance after transplantation for myeloma.
M. Attal, C. Cristini, G. Marit, D. Caillot, T. Facon, C. Hullin, P. Moreau, C. Mathiot, H. Avet-Loiseau, J. L. Harousseau.
Oral Abstract Session: Myeloma, Abstract 8018
Time: 9:30 AM to 12:30 PM
Location: E354b
Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM):
Final results of a multicenter phase I/II study.
K. C. Anderson, E. Weller, S. Lonial, A. J. Jakubowiak, S. Jagannath, N. S. Raje, D. Avigan, R. D. Knight, D. Esseltine,
P. G. Richardson.
Oral Abstract Session: Myeloma, Abstract 8016
Time: 9:30 AM to 12:30 PM
Location: E354b
Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous
stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104.
P. L. McCarthy, K. Owzar, K. C. Anderson, C. C. Hofmeister, H. Hassoun, D. D. Hurd, E. A. Stadtmauer, S. Giralt,
V. Hars, C. A. Linker.
Oral Abstract Session: Myeloma, Abstract 8017
Time: 9:30 AM to 12:30 PM
Location: E354b
Monday, June 7, 2010
Trials in Progress Poster Session
PANORAMA 2: A phase II study of panobinostat (LBH589) in combination with bortezomib (BTZ) and
dexamethasone (DEX) in patients with relapsed and BTZ-refractory multiple myeloma (MM).
M. Alsina, S. Lonial, D. M. Weber, S. E. Coutre, B. P. Kang, T. Glynos, G. Warsi, S. M. Snodgrass, P. G. Richardson.
Trials in Progress Poster Session Abstract TPS 308
Time: 8:00 AM to 12:00 PM
Location: S Hall A2
Phase II multisite study to evaluate efficacy and safety of single weekly administration of bortezomib (BZ)
and dexmethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts).
N. C. Munshi, S. Lee, G. D. Roodman, C. Behler, S. Kambhampati, M. G. Rose, M. T. Brophy, A. Houranieh,
D. Esseltine, A. Lichtenstein.
Trials in Progress Poster Session Abstract TPS 307
Time: 8:00 AM to 12:00 PM
Location: S Hall A2
www.myeloma.org
(800) 452 - CURE (2873)
Publication Only Abstracts
A retrospective database analysis of treatment patterns and outcomes for multiple myeloma (MM)
patients with malignant bone lesions (BM).
D. Spencer, J. R. Perez-Torrealba, S. Kaura, H. J. Henk.
J Clin Oncol 28, 2010 (suppl); Abstract e18506
Allogeneic (allo) stem cell transplant (SCT) for multiple myeloma (MM):
A retrospective single center analysis.
E. Medvedova, J. Cerny, R. Nath.
J Clin Oncol 28, 2010 (suppl) Abstract e18536
Carfilzomib (CFZ) in combination with DEX and other agents (Dox, Thal, DDP, vorinostat) for far advanced
and refractory multiple myeloma (FARMM).
Y. Alsayed, B. P. Nair, M. Kauffman, N. Petty, S. Waheed, F. Van Rhee, J. Szymonifka, B. Barlogie.
J Clin Oncol 28, 2010 (suppl); Abstract e18504
Comprehensive assessment (CA) of organ function and comorbidities in a large consecutive multiple
myeloma patient cohort.
D. De Pasquale, M. Kleber, G. Ihorst, M. Terhorst, B. Deschler, M. M. Engelhardt.
J Clin Oncol 28, 2010 (suppl); Abstract e18523
Effect of race, age, and gender on prognosis in total therapy protocols for multiple myeloma.
J. Szymonifka, J. D. Shaughnessy, A. Hoering, Y. Alsayed, S. Waheed, B. P. Nair, J. Crowley, B. Barlogie.
J Clin Oncol 28, 2010 (suppl); Abstract e18502
Effectiveness and patterns of bortezomib use in real-life practice: Results of VESUVE, a French cohort study.
Fourrier-Réglat, H. Eghbali, T. Facon, J. Fermand, O. Fitoussi, G. Marit, A. Grelaud, E. Bignon, J. Jove, N. Moore.
J Clin Oncol 28, 2010 (suppl); Abstract e18522
Effects of Vitaxin on hyperactive osteoclastogenesis in multiple myeloma: A preclinical study.
L. S. Stucci, M. De Matteo, M. Cives, M. Tucci, F. Silvestris.
J Clin Oncol 28, 2010 (suppl); Abstract e18501
Impact of radiotherapy on pain relief and recalcification in patients affected by plasma cell neoplasms:
A long-term experience.
S. Manfrida, S. Chiesa, E. Rossi, V. Frascino, G. Mantini, G. R. D'Agostino, B. De Bari, M. De Santis, V. De Stefano,
M. Balducci.
J Clin Oncol 28, 2010 (suppl); Abstract e18558
Lower-dose dexamethasone (Dex)/thalidomide (Thal) and zoledronic acid (ZOL) every 3 weeks in previously
untreated multiple myeloma.
G. Teoh, Y. Chen, K. Kim, A. Srivastava, V. R. Pai, S. Yoon, C. Suh, Y. Kim.
J Clin Oncol 28, 2010 (suppl); Abstract e18524
www.myeloma.org
(800) 452 - CURE (2873)
Overall survival (OS) and time to failure (TTF) associated with anti-myeloma therapy
in a U.S. managed-care population.
L. Ma, K. L. Stevinson, T. A. Burke, S. Kumar.
J Clin Oncol 28, 2010 (suppl); Abstract e18505
Outcome and prognostic factors in solitary plasmacytoma.
V. K. Reed, J. J. Shah, A. Mazloom, D. M. Weber, J. Phan, R. Z. Orlowski, S. K. Thomas, M. Wang, R. Alexanian,
B. S. Dabaja.
J Clin Oncol 28, 2010 (suppl); Abstract e18512
Phase I dose-escalation (DE) trial of high-dose melphalan (M) with palifermin (P) for cytoprotection
followed by autologous stem cell transplantation (ASCT) for myeloma (MM) patients with abnormal
renal function (AbRF).
N. Tageja, Z. S. Al-Kadhimi, S. Cronin, J. Abrams, M. Ventimiglia, L. G. Lum, L. J. Ayash, V. Ratanatharathorn,
J. P. Uberti, M. H. Abidi.
J Clin Oncol 28, 2010 (suppl); Abstract e18560
Quality of bone marrow biopsy as compared to the 2008 WHO guidelines.
A. M. Padurean.
J Clin Oncol 28, 2010 (suppl); Abstract e17005
Thalidomide-induced cardiotoxicity in multiple myeloma patients: An underestimated but clinically
relevant issue.
E. Arboscello, A. Bellodi, C. Passalia, P. Spallarossa, E. Balleari, I. Ponassi, A. Calvia, L. Canepa, M. C. Casale, R. Ghio.
J Clin Oncol 28, 2010 (suppl); Abstract e18544
The role of radiation therapy for multiple myeloma in the era of novel agents.
K. K. Abbi, H. Wagner, J. J. Drabick, T. P. Loughran, G. Talamo
J Clin Oncol 28, 2010 (suppl); Abstract e18557
Use of an ex vivo multiplexed signal pathway inhibitor treatment to reveal sensitivity of myeloma and
nonmyeloma bone marrow cell populations.
L. A. Liotta, A. Romano, A. VanMeter, G. J. Orloff, A. I. Spira, D. Patel, D. Dunning, L. Steger, E. Petricoin III,
V. A. Espina.
J Clin Oncol 28, 2010 (suppl); Abstract e18532
www.myeloma.org
(800) 452 - CURE (2873)
(800)452-CURE (2873)
www.myeloma.org